A Systematic Review of the Current Evidence of the Effectiveness and Safety of Immunoprophylaxis Using Sublingual Dead Whole Bacteria to Prevent Recurrent Urinary Tract Infections (rUTIs)
Abstract
Background/Objectives: Recurrent urinary tract infections (rUTIs) remain a major clinical challenge, but sublingual immunoprophylaxis with inactivated whole bacteria is a promising alternative to antibiotic prophylaxis. The objective of this systematic review was to assess the efficacy and safety of sublingual bacterial vaccines. Methods: We searched MEDLINE, Cochrane CENTRAL, and Embase (January 1979–August 2025) for English-language studies evaluating bacterial vaccines for rUTI prevention. Eligible studies included adults receiving sublingual immunoprophylaxis with heat-inactivated whole bacteria. Outcomes were UTI recurrence, infection-free interval, and adverse events. Both MV140 and autovaccines were assessed. Results: Of the 262 records identified, 14 studies met the inclusion criteria (4 comparatives, including 1 randomized trial, and 10 observational studies). UTI incidence decreased from 3.2–6.8 to 0–1.5 episodes/year at 12 months. The proportion of UTI-free patients ranged from 9.8 to 90% with immunoprophylaxis versus 0 to 25% with antibiotics or placebo. At 12 months, UTI-free rates were 10–49% with autovaccines and 9.7–60% with MV140. Patients with ≥3 UTIs ranged from 14.3 to 60.2% and 20 to 56.1% with autovaccines and MV140, respectively. The RCT reported adverse events in 0–40.8% of treated patients and 50% of placebo patients, predominantly mild. Conclusions: Although the available evidence is heterogeneous and largely derived from observational studies,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.